TrHCROSS is the new generation of joint injections based on highly purified cross-linked hyaluronic acid.
One shot injecatble cross-linked hyaluronic acid viscosupplementation of synovial fluid when its viscosity has been reduced due to knee osteoarthritis (KOA) process.
+ Reduces the pain and increases the functionality of the affected joint.
+ Provides a lubricant and shock-absortion effect on the affected joint.
+ Improves the quality of life of the patient
Do you want to know more?
Fill in the following details and one of our sales representatives will contact you shortly.
With just one injection, TrHCROSS can relieve pain for up to 6 months.
Supplementing natural joint fluid and replenishing lubricating and cushioning functions.
Higher viscosity is associated with greater implant durability.
More effective effect in reducing pain and a greater cushioning capacity compared to other competitors.
+ European product: All the ingredients we use are 100% European origin, and the products are entirely manufactured at our facilities in the north of Spain.
+ MDR certificate: The submission, clinical trials and documentation required to obtain the MDR certificate have been submitted and we expect to receive it in 2024.
+ Wide range: We offer viscosupplements of different strengths so doctors can choose what best adjusts to their needs and mode of work.
+ Hyaluronic Acid specialization: We have been working with this complex polymer for 10 years. We not only add HA to our products, but we master it to explode its potential and obtain high-added value injectables.
+ Formulations: We carefully selected our HA’s molecular weight and polymer chain length to make it optimal for its purpose.
+ Non-animal origin HA
+ SARE Technology®: we have a proprietary cross-linking technology with innovative capabilities, superior to other products on the market in aspects such as bio-integration, low endotoxin, elasticity and viscosity.
+ Available for distribution worldwide